BR0317573A - Agentes de receptores de linfotoxina beta em combinação com agentes quimioterapêuticos - Google Patents

Agentes de receptores de linfotoxina beta em combinação com agentes quimioterapêuticos

Info

Publication number
BR0317573A
BR0317573A BR0317573-1A BR0317573A BR0317573A BR 0317573 A BR0317573 A BR 0317573A BR 0317573 A BR0317573 A BR 0317573A BR 0317573 A BR0317573 A BR 0317573A
Authority
BR
Brazil
Prior art keywords
agents
combination
beta
chemotherapeutic agents
lymphotoxin receptor
Prior art date
Application number
BR0317573-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Doreen Lepage
Alan Gill
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of BR0317573A publication Critical patent/BR0317573A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR0317573-1A 2002-12-20 2003-12-22 Agentes de receptores de linfotoxina beta em combinação com agentes quimioterapêuticos BR0317573A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43518502P 2002-12-20 2002-12-20
PCT/US2003/041243 WO2004058183A2 (en) 2002-12-20 2003-12-22 Lymphotoxin beta receptor agents in combination with chemotherapeutic agents

Publications (1)

Publication Number Publication Date
BR0317573A true BR0317573A (pt) 2005-11-22

Family

ID=32682180

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317573-1A BR0317573A (pt) 2002-12-20 2003-12-22 Agentes de receptores de linfotoxina beta em combinação com agentes quimioterapêuticos

Country Status (16)

Country Link
US (1) US20060134102A1 (https=)
EP (1) EP1585547A4 (https=)
JP (1) JP2006513225A (https=)
KR (1) KR20050094819A (https=)
CN (1) CN1753692A (https=)
AU (1) AU2003303339A1 (https=)
BR (1) BR0317573A (https=)
CA (1) CA2509495A1 (https=)
EA (1) EA200501019A1 (https=)
IS (1) IS7900A (https=)
MX (1) MXPA05006663A (https=)
NO (1) NO20053529L (https=)
PL (1) PL377611A1 (https=)
RS (1) RS20050481A (https=)
WO (1) WO2004058183A2 (https=)
ZA (1) ZA200505543B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
PL366307A1 (en) * 2000-10-13 2005-01-24 Biogen, Inc. Humanized anti-lt-beta-r antibodies
CA2491480A1 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies
EP1539235A2 (en) * 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
NZ544924A (en) * 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
KR20060132006A (ko) 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
PT2343320T (pt) 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
WO2006125632A2 (en) * 2005-05-24 2006-11-30 Rechtsanwalt Dr. Martin Prager Als Insolvenzverwalter Über Das Vermögen Der Xantos Biomedicine Ag, Pluta Rechtsanwalts Gmbh Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy
EP2040751A2 (en) * 2006-06-15 2009-04-01 Biogen Idec MA Inc. Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents
UA94484C2 (uk) 2006-10-12 2011-05-10 Дженентек, Інк. Антитіла до лімфотоксину-альфа
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
CN101600450A (zh) * 2006-10-20 2009-12-09 比奥根艾迪克Ma公司 利用可溶性淋巴毒素β受体的脱髓鞘病的治疗
US8591886B2 (en) * 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
MX389194B (es) 2015-10-06 2025-03-20 Univ Minnesota Compuestos terapéuticos y métodos.
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
WO2019238966A1 (en) * 2018-06-15 2019-12-19 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
KR102232659B1 (ko) * 2018-07-16 2021-03-26 전북대학교 산학협력단 항원전달용 폴리펩타이드, 이를 포함하는 Fc-융합 단백질 및 이의 용도
CN112912400B (zh) 2018-10-19 2025-05-30 明尼苏达大学董事会 Nk接合子分子及其使用方法
CA3164226A1 (en) * 2019-12-11 2021-06-17 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
CN117327174A (zh) * 2022-06-24 2024-01-02 广东菲鹏制药股份有限公司 抗新型冠状病毒人源化多价结合蛋白及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
KR100475492B1 (ko) * 1995-01-26 2005-03-14 바이오겐 아이덱 엠에이 인코포레이티드 항종양제로서의 림프독소-α/β 복합체 및항-림프독소-β수용체 항체
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
KR100584704B1 (ko) * 1996-10-25 2006-05-30 바이오겐 아이덱 엠에이 인코포레이티드 면역 질환을 치료하기 위한 치료제로서의 가용성 림포톡신-베타 수용체, 항림포톡신 수용체 항체 및 항림포톡신 리간드 항체
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
PL366307A1 (en) * 2000-10-13 2005-01-24 Biogen, Inc. Humanized anti-lt-beta-r antibodies
US7361343B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
CA2491480A1 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
KR20060132006A (ko) * 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도

Also Published As

Publication number Publication date
IS7900A (is) 2005-06-20
EP1585547A4 (en) 2006-10-25
JP2006513225A (ja) 2006-04-20
AU2003303339A1 (en) 2004-07-22
NO20053529L (no) 2005-09-20
EP1585547A2 (en) 2005-10-19
US20060134102A1 (en) 2006-06-22
WO2004058183A3 (en) 2004-12-09
RS20050481A (sr) 2007-08-03
ZA200505543B (en) 2006-12-27
WO2004058183A2 (en) 2004-07-15
CN1753692A (zh) 2006-03-29
NO20053529D0 (no) 2005-07-19
PL377611A1 (pl) 2006-02-06
EA200501019A1 (ru) 2006-06-30
MXPA05006663A (es) 2005-09-30
CA2509495A1 (en) 2004-07-15
KR20050094819A (ko) 2005-09-28

Similar Documents

Publication Publication Date Title
BR0317573A (pt) Agentes de receptores de linfotoxina beta em combinação com agentes quimioterapêuticos
BR9814923A (pt) Método para tratamento de doença de alzheimer
BR0013122A (pt) Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
BRPI0408247A (pt) usos de antagonistas e agonistas de il-23 e reagentes relacionados
BR0116575A (pt) Terapia combinada que usa inibidores de tirosina cinase receptora e inibidores de angiogênese
BR0310099A (pt) método para tratar dislipidemia ou uma doença associada com a dislipidemia
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
CY1112387T1 (el) Θεραπευτικη συνθεση περιεχουσα τουλαχιστον ενα παραγωγο της πυρρολοβενζοδιαζεπινης και φλουδαραβινη
ECSP077401A (es) Medicamentos que contienen compuestos de carbonilo y su uso
BRPI0414277A (pt) métodos e composições para o tratamento de dor e outras condições mediadas adrenérgicas alfa 2
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
BR0211915A (pt) Execução de aplicação habilitada para teste
BRPI0410503B8 (pt) composição tópica e uso da composição
BRPI0414876A (pt) compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
UY28213A1 (es) Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
BR0207977A (pt) Métodos de combinação de inibição de crescimento tumoral com um antagonista de receptor de fator de crescimento endotelial
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
BR0011172A (pt) Derivados do 4,5-diaril-3(2h)-furanona como inibidores de cliclooxigenase-2
BR0307508A (pt) Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença
BRPI0516531A (pt) imunoterapia de distúrbios auto-imunes
BRPI0412919A (pt) combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos
BR0313470A (pt) Combinações terapêuticas de inibidores erbb quinase e terapias antineoplásicas
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
SV2006002342A (es) Terapia de antiogenesis para enfermedades autoinmunes en pacientes que tuvieron la terapia anterior interrumpida

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.